Immunological principles of T-cell-mediated adverse drug reactions in skin

Expert Opinion on Drug Safety

Volumn 6, Issue 2, 2007, Pages 109-124

  Naisbitt, Dean J ^a   Pirmohamed, Munir ^a   Park, B Kevin ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Covalent binding; Drug hypersensitivity; Drug metabolism; T cells

Indexed keywords

ABACAVIR; AMOXICILLIN; ANTICONVULSIVE AGENT; ANTIINFECTIVE AGENT; ANTIRETROVIRUS AGENT; CARBAMAZEPINE; CD40 ANTIGEN; CELL SURFACE RECEPTOR; COTRIMOXAZOLE; DICLOFENAC; DRUG METABOLITE; LAMOTRIGINE; NEVIRAPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN DERIVATIVE; PENICILLIN G; SULFAMETHOXAZOLE; SULFONAMIDE;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL MIGRATION; CELLULAR IMMUNITY; CYTOKINE RELEASE; CYTOTOXICITY; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INCIDENCE; INNATE IMMUNITY; KERATINOCYTE; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; OPPORTUNISTIC INFECTION; PHENOTYPE; PROTEIN MODIFICATION; REVIEW; SIGNAL TRANSDUCTION; SKIN INFLAMMATION; STEVENS JOHNSON SYNDROME; T LYMPHOCYTE; TOXIC EPIDERMAL NECROLYSIS;

ANIMALS; DRUG HYPERSENSITIVITY; HUMANS; PHARMACEUTICAL PREPARATIONS; SKIN DISEASES; T-LYMPHOCYTES;

EID: 33847744634     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.6.2.109     Document Type: Review

References (163)

1. PARK BK, PIRMOHAMED M, KITTERINGHAM NR: Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective. Chem. Res. Toxicol. (1998) 11(9):969-988.
2. UETRECHT J: Prediction of a new drug's potential to cause idiosyncratic reactions. Curr. Opin. Drug Discov. Devel. (2001) 4(1):55-59.
3. BIGBY M, JICK S, JICK H, ARNDT K: Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA (1986) 256(24):3358-3363.
4. ROUJEAU JC: Clinical heterogeneity of drug hypersensitivity. Toxicology (2005) 209(2):123-129.
5. NYFELER B, PICHLER WJ: The lymphocyte transformation test for the diagnosis of drug allergy: sensitivity and specificity. Clin. Exp. Allergy (1997) 27:175-181.
6. HARI Y, FRUTIG-SCHNYDER K, HURNI M et al.: T cell involvement in cutaneous drug eruptions. Clin. Exp. Allergy (2001) 31(9):1398-1408.
7. PICHLER WJ, TILCH J: The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy (2004) 59(8):809-820.
8. + T cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine. J. Immunol. (1995) 155(1):462-472.
9. BEELER A, ENGLER O, GERBER BO, PICHLER WJ: Long-lasting reactivity and high frequency of drug-specific T cells after severe systemic drug hypersensitivity reactions. J. Allergy Clin. Immunol. (2006) 117(2):455-462.
10. WU Y, SANDERSON JP, FARRELL J et al.: Activation of T cells by carbamazepine and carbamazepine metabolites. J. Allergy Clin. Immunol. (2006) 118(1):233-241.
11. NASSIF A, BENSUSSAN A, BOUMSELL L et al.: Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J. Allergy Clin. Immunol. (2004) 114(5):1209-1215.
12. SCHAERLI P, BRITSCHGI M, KELLER M et al.: Characterization of human T cells that regulate neutrophilic skin inflammation. J. Immunol. (2004) 173(3):2151-2158.
13. FRIEDMANN PS, STRICKLAND I, PIRMOHAMED M, PARK BK: Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine. Arch. Dermatol. (1994) 130(5):598-604.
14. BACHOT N, ROUJEAU JC: Differential diagnosis of severe cutaneous drug eruptions. Am. J. Clin. Dermatol. (2003) 4(8):561-572.
15. YAWALKAR N, HARI Y, FRUTIG K et al.: T cells isolated from positive epicutaneous test reactions to amoxicillin and ceftriaxone are drug specific and cytotoxic. J. Invest. Dermatol. (2000) 115(4):647-652.
16. + T cells from allergic individuals. J. Immunol. (2000) 164(12):6647-6654.
17. NAISBITT DJ, FARRELL J, WONG G et al.: Characterization of drug-specific T cells in lamotrigine hypersensitivity. J. Allergy Clin. Immunol. (2003) 111(6):1393-1403.
18. NAISBITT DJ, BRITSCHGI M, WONG G et al.: Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. Mol. Pharmacol. (2003) 63(3):732-741.
19. PICHLER WJ: Lessons from drug allergy: against dogmata. Curr. Allergy Asthma Rep. (2003) 3(1):1-3.
20. KUECHLER PC, BRITSCHGI M, SCHMID S et al.: Cytotoxic mechanisms in different forms of T-cell-mediated drug allergies. Allergy (2004) 59(6):613-622.
21. YAWALKAR N, SHRIKHANDE M, HARI Y et al.: Evidence for a role for IL-5 and eotaxin in activating and recruiting eosinophils in drug-induced cutaneous eruptions. J. Allergy Clin. Immunol. (2000) 106(6):1171-1176.
22. BRITSCHGI M, STEINER UC, SCHMID S et al.: T-cell involvement in drug-induced acute generalized exanthematous pustulosis. J. Clin. Invest. (2001) 107(11):1433-1441.
23. SCHNYDER B, FRUTIG K, MAURI-HELLWEG D et al.: T-cell-mediated cytotoxicity against keratinocytes in sulfamethoxazole-induced skin reaction. Clln. Exp. Allergy (1998) 28:1412-1417.
24. PICHLER WJ: Delayed drug hypersensitivity reactions. Ann. Intern. Med. (2003) 139(8):683-693.
25. SCHNYDER B, MAURI-HELLWEG D, ZANNI M, BETTENS F, PICHLER WJ: Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones. J. Clin. Invest. (1997) 100(1):136-141.
26. + T-cell clones. Nature (1988) 335(6191):642-644.
27. + T-cells from carbamazepine hypersensitive patients. Br. J. Clin. Pharmacol. (2006) 61(5):632-632.
28. +) T cells are differentiated effector memory cells with antiviral functions. Blood (2004) 104(2):478-486.
29. + (thymocyte-like) T lymphocytes present in blood and skin from patients with atopic dermatitis suggest immune dysregulation. Br. J. Dermatol. (2001) 144(6):1140-1147.
30. +) cells and other unusual phenotypes are frequently detected among spontaneously interleukin 2-responsive T lymphocytes present in the joint fluid in juvenile rheumatoid arthritis. A clonal analysis. Eur. J. Immunol. (1987) 17(12):1815-1819.
31. SHENTON JM, POPOVIC M, CHEN J, MASSON MJ, UETRECHT JP: Evidence of an immune-mediated mechanism for an idiosyncratic nevirapine-induced reaction in the female Brown Norway rat. Chem. Res. Toxicol. (2005) 18(12):1799-1813.
32. SHENTON JM, TERANISHI M, ABU-ASAB MS, YAGER JA, UETRECHT JP: Characterization of a potential animal model of an idiosyncratic drug reaction: nevirapine-induced skin rash in the rat. Chem. Res. Toxicol. (2003) 16(9):1078-1089.
33. ENGLER OB, STRASSER I, NAISBITT DJ, CERNY A, PICHLER WJ: A chemically inert drug can stimulate T cells in vitro by their T cell receptor in non-sensitised individuals. Toxicology (2004) 197(1):47-56.
34. KELLER M, SPANOU Z, SCHAERLI P et al.: T cell-regulated neutrophilic inflammation in autoinflammatory diseases. J. Immunol. (2005) 175(11):7678-7686.
35. + T cell clones. J. Immunol. (1999) 162(1):595-602.
36. VALITUTTI S, MULLER S, CELLA M, PADOVAN E, LANZAVECCHIA A: Serial triggering of many T-cell receptors by a few peptide-MHC complexes. Nature (1995) 375(6527):148-151.
37. VALITUTTI S, DESSING M, AKTORIES K, GALLATI H, LANZAVECCHIA A: Sustained signaling leading to T cell activation results from prolonged T cell receptor occupancy. Role of T cell actin cytoskeleton. J. Exp. Med. (1995) 181(2):577-584.
38. VIOLA A, LANZAVECCHIA A: T cell activation determined by T cell receptor number and tunable thresholds. Science (1996) 273(5271):104-106.
39. CAMPBELL DJ, KIM CH, BUTCHER EC: Chemokines in the systemic organization of immunity. Immunol. Rev. (2003) 195:58-71.
40. LEYVA L, TORRES MJ, POSADAS S et al.: Anticonvulsant-induced toxic epidermal necrolysis: monitoring the immunologic response. J. Allergy Clin. Immunol. (2000) 105(1 Pt 1):157-165.
41. HOMEY B, ALENIUS H, MULLER A et al.: CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat. Med. (2002) 8(2):157-165.
42. +) skin homing T cells. J. Immunol. (2002) 169(3): 1189-1196.
43. MOED H, BOORSMA DM, TENSEN CP et al.: Increased CCL27-CCR10 expression in allergic contact dermatitis: implications for local skin memory. J. Pathol. (2004) 204(1):39-46.
44. + and express chemokine receptors CXCR3, CCR4 and CCR10. Br. J. Dermatol. (2004) 151(1):32-41.
45. VESTERGAARD C, DELEURAN M, GESSER B, GRONHOJ LARSEN C: Expression of the T-helper 2-specific chemokine receptor CCR4 on CCR10-positive lymphocytes in atopic dermatitis skin but not in psoriasis skin. Br. J. Dermatol. (2003) 149(3):457-463.
46. SOLER D, HUMPHREYS TL, SPINOLA SM, CAMPBELL JJ: CCR4 versus CCR10 in human cutaneous TH lymphocyte trafficking. Blood (2003) 101(5):1677-1682.
47. SCHAERLI P, EBERT L, WILLIMANN K et al.: A skin-selective homing mechanism for human immune surveillance T cells. J. Exp. Med. (2004) 199(9):1265-1275.
48. SOZZANI S, ALLAVENA P, D'AMICO G et al.: Differential regulation of chemokine receptors during dendritic cell maturation: a model for their trafficking properties. J. Immunol. (1998) 161(3):1083-1086.
49. DIEU MC, VANBERVLIET B, VICARI A et al.: Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J. Exp. Med. (1998) 188(2):373-386.
50. DUDDA JC, LEMBO A, BACHTANIAN E et al.: Dendritic cells govern induction and reprogramming of polarized tissue-selective homing receptor patterns of T cells: important roles for soluble factors and tissue microenvironments. Eur. J. Immunol. (2005) 35(4):1056-1065.
51. DUDDA JC, MARTIN SF: Tissue targeting of T cells by DCs and microenvironments. Trends Immunol. (2004) 25(8):417-421.
52. + T cell trafficking to inflamed skin: role for tissue microenvironment and dendritic cells in establishment of T cell-homing subsets. J. Immunol. (2004) 172(2):857-863.
53. GODDARD S, YOUSTER J, MORGAN E, ADAMS DH: Interleukin-10 secretion differentiates dendritic cells from human liver and skin. Am. J. Pathol. (2004) 164(2):511-519.
54. + T cells. J. Immunol. (1999) 162(6):3256-3262.
55. CURTSINGER JM, LINS DC, MESCHER MF: Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J. Exp. Med. (2003) 197(9):1141-1151.
56. NIERKENS S, NIEUWENHUIJSEN L, THOMAS M, PIETERS R: Evaluation of the use of reporter antigens in an auricular lymph node assay to assess the immunosensitizing potential of drugs. Toxicol. Sci. (2004) 79(1):90-97.
57. PIETERS R, EZENDAM J, NIERKENS S: Chemical-specific properties co-determine the type of adverse immune response. Autoimmun. Rev. (2003) 2(1):25-29.
58. NIERKENS S, VAN HELDEN P, BOL M et al.: Selective requirement for CD40-CD154 in drug-induced type 1 versus type 2 responses to trinitrophenyl-ovalbumin. J. Immunol. (2002) 168(8):3747-3754.
59. H2 cell-promoting dendritic cells in vitro with diverse th cell-polarizing signals. J. Immunol. (2002) 168(4):1704-1709.
60. CUMBERBATCH M, CLELLAND K, DEARMAN RJ, KIMBER I: Impact of cutaneous IL-10 on resident epidermal Langerhans' cells and the development of polarized immune responses. J. Immunol. (2005) 175(1):45-50.
61. HOPKINS JE, NAISBITT DJ, KITTERINGHAM NR et al.: Selective haptenation of cellular or extracellular protein by chemical allergens: association with cytokine polarization. Chem. Res. Toxicol. (2005) 18(2):375-381.
62. DESCAMPS V, VALANCE A, EDLINGER C et al.: Association of human herpes virus 6 infection with drug reaction with eosinophilia and systemic symptoms. Arch. Dermatol. (2001) 137(3):301-304.
63. UETRECHT JP: New concepts in immunology relevant to idiosyncratic drug reactions: the 'danger hypothesis' and innate immune system. Chem. Res. Toxicol. (1999) 12(5):387-395.
64. RIFKIN IR, LEADBETTER EA, BUSCONI L, VIGLIANTI G, MARSHAK-ROTHSTEIN A: Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol. Rev. (2005) 204:27-42.
65. SCHEIBNER KA, LUTZ MA, BOODOO S et al.: Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J. Immunol. (2006) 177(2):1272-1281.
66. BEERE HM: Death versus survival: functional interaction between the apoptotic and stress-inducible heat shock protein pathways. J. Clin. Invest. (2005) 115(10):2633-2639.
67. BEERE HM: 'The stress of dying': the role of heat shock proteins in the regulation of apoptosis. J. Cell Sci. (2004) 117(Pt 13):2641-2651.
68. SHI Y, GALUSHA SA, ROCK KL: Cutting edge: elimination of an endogenous adjuvant reduces the activation of CD8 T lymphocytes to transplanted cells and in an autoimmune diabetes model. J. Immunol. (2006) 176(7):3905-3908.
69. SHI Y, EVANS JE, ROCK KL: Molecular identification of a danger signal that alerts the immune system to dying cells. Nature (2003) 425(6957):516-521.
70. SHI Y, ROCK KL: Cell death releases endogenous adjuvants that selectively enhance immune surveillance of particulate antigens. Eur. J. Immunol. (2002) 32(1):155-162.
71. SHI Y, ZHENG W, ROCK KL: Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses. Proc. Natl. Acad. Sci. USA (2000) 97(26):14590-14595.
72. GALLUCCI S, LOLKEMA M, MATZINGER P: Natural adjuvants: endogenous activators of dendritic cells. Nat. Med. (1999) 5(11):1249-1255.
73. CARR A, TINDALL B, PENNY R, COOPER DA: In vitro cytotoxicity as a marker of hypersensitivity to sulphamethoxazole in patients with HIV. Clin. Exp. Immunol. (1993) 94(1):21-25.
74. REILLY TP, MACARTHUR RD, FARROUGH MJ et al.: Is hydroxylamine-induced cytotoxicity a valid marker for hypersensitivity reactions to sulfamethoxazole in human immunodeficiency virus-infected individuals? J. Pharmacol. Exp. Ther. (1999) 291:1356-1364.
75. PEARCE RE, UETRECHT JP, LEEDER JS: Pathways of carbamazepine bioactivation in vitro: II. The role of human cytochrome P450 enzymes in the formation of 2-hydroxyiminostilbene. Drug Metab. Dispos. (2005) 33(12):1819-1826.
76. PEARCE RE, VAKKALAGADDA GR, LEEDER JS: Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites. Drug Metab. Dispos. (2002) 30(11):1170-1179.
77. MAGGS JL, NAISBITT DJ, TETTEY JN, PIRMOHAMED M, PARK BK: Metabolism of lamotrigine to a reactive arene oxide intermediate. Chem. Res. Toxicol. (2000) 13(11):1075-1081.
78. MADDEN S, MAGGS JL, PARK BK: Bioactivation of carbamazepine in the rat in-vivo - evidence for the formation of reactive arene oxide(s). Drug Metab. Dispos. (1996) 24:469-479.
79. GILL HJ, MAGGS JL, MADDEN S, PIRMOHAMED M, PARK BK: The effect of fluconazole and ketoconazole on the metabolism of sulphamethoxazole. Br. J. Clin. Pharmacol. (1996) 42(3):347-353.
80. CRIBB AE, SPIELBERG SP: Sulfamethoxazole is metabolized to the hydroxylamine in humans. Clin. Pharmacol. Ther. (1992) 51(5):522-526.
81. REILLY TP, LASH LH, DOLL MA et al.: A role for bioactivation and covalent binding within epidermal keratinocytes in sulfonamide-induced cutaneous drug reactions. J Invest. Dermatol. (2000) 114(6):1164-1173.
82. BHAIYA P, ROYCHOWDHURY S, VYAS PM et al.: Bioactivation, protein haptenation, and toxicity of sulfamethoxazole and dapsone in normal human dermal fibroblasts. Toxicol. Appl. Pharmacol. (2006) 215(2):158-167.
83. ROYCHOWDHURY S, VYAS PM, REILLY TP, GASPARI AA, SVENSSON CK: Characterization of the formation and localization of sulfamethoxazole and dapsone-associated drug-protein adducts in human epidermal keratinocytes. J. Pharmacol. Exp. Ther. (2005) 314(1):43-52.
84. KHAN FD, ROYCHOWDHURY S, NEMES R et al.: Effect of pro-inflammatory cytokines on the toxicity of the arylhydroxylamine metabolites of sulphamethoxazole and dapsone in normal human keratinocytes. Toxicology (2006) 218(2-3):90-99.
85. VYAS PM, ROYCHOWDHURY S, WOSTER PM, SVENSSON CK: Reactive oxygen species generation and its role in the differential cytotoxicity of the arylhydroxylamine metabolites of sulfamethoxazole and dapsone in normal human epidermal keratinocytes. Biochem. Pharmacol. (2005) 70(2):275-286.
86. VYAS PM, ROYCHOWDHURY S, KHAN FD et al.: Enzyme-mediated protein haptenation of dapsone and sulfamethoxaozle in human keratinocytes - 1. Expression and role of cytochromes P450. J. Pharmacol. Exp. Ther. (2006) 319:488-496.
87. VYAS PM, ROYCHOWDHURY S, KOUKOURITAKI SB et al.: Enzyme-mediated protein haptenation of dapsone and sulfamethoxazole in human keratinocytes - 2. Expression and role of flavin-containing monooxygeanses and peroxidases. J. Pharmacol. Exp. Ther. (2006) 319: 496-505.
88. TREPANIER LA, YODER AR, BAJAD S et al.: Plasma ascorbate deficiency is associated with impaired reduction of sulfamethoxazole-nitroso in HIV infection. J. Acquir. Immune Defic. Syndr. (2004) 36(5):1041-1050.
89. NAISBITT DJ, VILAR FJ, STALFORD AC et al.: Plasma cysteine deficiency and decreased reduction of nitrososulfamethoxazole with HIV infection. AIDS Res. Hum. Retroviruses (2000) 16(18):1929-1938.
90. WALMSLEY SL, WINN LM, HARRISON ML, UETRECHT JP, WELLS PG: Oxidative stress and thiol depletion in plasma and peripheral blood lymphocytes from HIV-infected patients: toxicological and pathological implications. AIDS (1997) 11(14):1689-1697.
91. AIBA S, TERUNUMA A, MANOME H, TAGAMI H: Dendritic cells differently respond to haptens and irritants by their production of cytokines and expression of co-stimulatory molecules. Eur. J. Immunol. (1997) 27(11):3031-3038.
92. BRUCHHAUSEN S, ZAHN S, VALK E, KNOP J, BECKER D: Thiol antioxidants block the activation of antigen-presenting cells by contact sensitizers. J. Invest. Dermatol. (2003) 121(5):1039-1044.
93. BECKER D, VALK E, ZAHN S, BRAND P, KNOP J: Coupling of contact sensitizers to thiol groups is a key event for the activation of monocytes and monocyte-derived dendritic cells. J. Invest. Dermatol. (2003) 120(2):233-238.
94. HULETTE BC, RYAN CA, GILDEA LA, GERBERICK GF: Relationship of CD86 surface marker expression and cytotoxicity on dendritic cells exposed to chemical allergen. Toxicol. Appl. Pharmacol. (2005) 209(2):159-166.
95. SANDERSON JP, NAISBITT DJ, FARRELL J et al.: Dendritic cell metabolism of sulfamethoxazole leads to increased CD40 expression: a key determinant of immunogenicity. Br. J. Clin. Pharmacol. (2006) 61(5):645-645.
96. SANDERSON JP, NAISBITT DJ, PARK BK: Role of bioactivation in drug-induced hypersensitivity reactions. AAPS J. (2006) 8(1):E55-E64.
97. LANDSTEINER K, JACOBS J: Studies on the sensitization of animals with simple chemical compounds. J. Exp. Med. (1935) 61:643-656.
98. WELTZIEN HU, MOULON C, MARTIN S et al.: T cell immune responses to haptens. Structural models for allergic and autoimmune reactions. Toxicology (1996) 107(2):141-151.
99. KOHLER J, MARTIN S, PFLUGFELDER U et al.: Cross-reactive trinitrophenylated peptides as antigens for class II major histocompatibility complex-restricted T cells and inducers of contact sensitivity in mice. Limited T cell receptor repertoire. Eur. J. Immunol. (1995) 25(1):92-101.
100. MARTIN S, VON BONIN A, FESSLER C, PFLUGFELDER U, WELTZIEN HU: Structural complexity of antigenic derminants for class I MHC-restricted, hapten-specific T cells. J. Immunol. (1993) 151:678-687.
101. BRANDER C, MAURI-HELLWEG D, BETTENS F et al.: Heterogeneous T-cell responses to beta-lactam-modified self structures are observed in penicillin-allergic individuals. J. Immunol. (1995) 155(5):2670-2678.
102. GERBERICK GF, RYAN CA, KERN PS et al.: A chemical dataset for evaluation of alternative approaches to skin-sensitization testing. Contact Dermatitis (2004) 50(5):274-288.
103. ELAHI EN, WRIGHT Z, HINSELWOOD D et al.: Protein binding and metabolism influence the relative skin sensitization potential of cinnamic compounds. Chem. Res. Toxicol. (2004) 17(3):301-310.
104. DIVKOVIC M, PEASE CK, GERBERICK GF, BASKETTER DA: Hapten-protein binding: from theory to practical application in the in vitro prediction of skin sensitization. Contact Dermatitis (2005) 53(4):189-200.
105. 13C]-dimethyl-p-benzoquinonediimine. Chem. Res. Toxicol. (2006) 19(9):1248-1256.
106. MASTERS PA, O'BRYAN TA, ZURLO J, MILLER DQ, JOSHI N: Trimethoprim-sulfamethoxazole revisited. Arch. Intern. Med. (2003) 163(4):402-410.
107. VAN DER VEN AJ, KOOPMANS PP, VREE TB, VAN DER MEER JW: Adverse reactions to co-trimoxazole in HIV infection. Lancet (1991) 338(8764):431-433.
108. CARR A, COOPER DA: Pathogenesis and management of HIV-associated drug hypersensitivity. AIDS Clin. Rev. (1995) 96:65-97.
109. CRIBB AE, SPIELBERG SP, GRIFFIN GP: N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes. Drug Metab. Dispos. (1995) 23(3):406-414.
110. VAN DERVEN AJ, MANTEL MA, VREE TB, KOOPMANS PP, VAN DER MEER JW: Formation and elimination of sulphamethoxazole hydroxylamine after oral administration of sulphamethoxazole. Br. J. Clin. Pharmacol. (1994) 38(2):147-150.
111. MITRA AK, THUMMEL KE, KALHORN TF et al.: Inhibition of sulfamethoxazole hydroxylamine formation by fluconazole in human liver microsomes and healthy volunteers. Clin. Pharmacol. Ther. (1996) 59(3):332-340.
112. CRIBB AE, MILLER M, LEEDER JS, HILL J, SPIELBERG SP: Reactions of the nitroso and hydroxylamine metabolites of sulfamethoxazole with reduced glutathione. Implications for idiosyncratic toxicity. Drug Metab. Dispos. (1991) 19(5):900-906.
113. NAISBITT DJ, O'NEILL PM, PIRMOHAMED M, PARK BK: Synthesis and reactions of nitroso sulfamethoxazole with biological nucleophiles - implications for immune-mediated toxicity. Bioorg. Med. Chem. Let (1996) 6:1511-1516.
114. NAISBITT DJ, FARRELL J, GORDON SF et al.: Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatibility complex-restricted antigen presentation. Mol. Pharmacol. (2002) 62(3):628-637.
115. 5 catalyze the microsomal reduction of xenobiodc hydroxylamines and amidoximes in humans. J. Pharmacol. Exp. Ther. (2004) 311(3):1171-1178.
116. NAISBITT DJ, GORDON SF, PIRMOHAMED M et al.: Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism-dependent haptenation and T-cell proliferation in vivo. Br. J. Pharmacol. (2001) 133(2):295-305.
117. NAISBITT DJ, HOUGH SJ, GILL HJ et al.: Cellular disposition of sulphamethoxazole and its metabolites: implications for hypersensitivity. Br. J. Pharmacol. (1999) 126(6):1393-1407.
118. MANCHANDA T, HESS D, DALE L, FERGUSON SG, RIEDER MJ: Haptenation of sulfonamide reactive metabolites to cellular proteins. Mol. Pharmacol. (2002) 62(5):1011-1026.
119. SUMMAN M, CRIBB AE: Novel non-labile covalent binding of sulfamethoxazole reactive metabolites to cultured human lymphoid cells. Chem. Biol. Interact. (2002) 142(1-2):155-173.
120. REILLY TP, LASH LH, DOLL MA et al.: A role for bioactivation and covalent binding within epidermal keratinocytes in sulfonamide-induced cutaneous drug reactions. J. Invest. Dermatol. (2000) 114(6):1164-1173.
121. NASSIF A, BENSUSSAN A, DOROTHEE G et al.: Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J. Invest. Dermatol. (2002) 118(4):728-733.
122. FARRELL J, NAISBITT DJ, DRUMMOND NS et al.: Characterization of sulfamethoxazole and sulfamethoxazole metabolite-specific T-cell responses in animals and humans. J. Pharmacol. Exp. Ther. (2003) 306(1):229-237.
123. GILL HJ, HOUGH SJ, NAISBITT DJ et al.: The relationship between the disposition and immunogenicity of sulfamethoxazole in the rat. J. Pharmacol. Exp. Ther. (1997) 282(2):795-801.
124. + T-cells. Br. J. Pharmacol. (2001) 132(3):623-630.
125. SCHMID DA, DEPTA JP, LUTHI M, PICHLER WJ: Transfection of drug-specific T-cell receptors into hybridoma cells: tools to monitor drug interaction with T-cell receptors and evaluate cross-reactivity to related compounds. Mol. Pharmacol. (2006) 70(1):356-365.
126. DEPTA JP, ALTZNAUER F, GAMERDINGER K et al.: Drug interaction with T-cell receptors: T-cell receptor density determines degree of cross-reactivity. J. Allergy Clin. Immunol. (2004) 113(3):519-527.
127. +) T cell clones. Int. Immunol. (2001) 13(7):877-885.
128. ZANNI MP, VON GREYERZ S, SCHNYDER B et al.: HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes. J. Clin. Invest. (1998) 102(8):1591-1598.
129. PICHLER WJ: Direct T-cell stimulations by drugs - bypassing the innate immune system. Toxicology (2005) 209(2):95-100.
130. MALLAL S, NOLAN D, WITT C et al.: Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet (2002) 359(9308):727-732.
131. MARTIN AM, NOLAN D, GAUDIERI S et al.: Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc. Natl. Acad. Sci. USA (2004) 101(12):4180-4185.
132. CHUNG WH, HUNG SI, HONG HS et al.: Medical genetics: a marker for Stevens-Johnson syndrome. Nature (2004) 428(6982):486.
133. HUNG SI, CHUNG WH, JEE SH et al.: Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet. Genomics (2006) 16(4):297-306.
134. LONJOU C, THOMAS L, BOROT N et al.: A marker for Stevens-Johnson syndrome.: ethnicity matters. Pharmacogenomics J. (2006) 6(4):265-268.
135. + natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol. Rev. (2006) 212:8-27.
136. SAKAGUCHI S, SAKAGUCHI N: Regulatory T cells in immunologic self-tolerance and autoimmune disease. Int. Rev. Immunol. (2005) 24(3-4):211-226.
137. +) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J. Exp. Med. (2005) 201(5):723-735.
138. + regulatory t cells for immunologic self-tolerance and negative control of immune responses. Ann. Rev. Immunol. (2004) 22:531-562.
139. + T cells. Adv. Immunol. (2003) 81:331-371.
140. + regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet (2004) 363(9409):608-615.
141. XYSTRAKIS E, BOSWELL SE, HAWRYLOWICZ CM: T regulatory cells and the control of allergic disease. Expert Opin. Biol. Ther. (2006) 6(2):121-133.
142. WAN YY, FLAVELL RA: The roles for cytokines in the generation and maintenance of regulatory T cells. Immunol. Rev. (2006) 212:114-130.
143. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. (1998) 188(2):287-296.
144. + naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int. Immunol. (1998) 10(12):1969-1980.
145. ROBINSON DS: The role of regulatory T lymphocytes in asthma pathogenesis. Curr. Allergy Asthma Rep. (2005) 5(2):136-141.
146. + T reg cells. J. Exp. Med. (2006) 203(7):1701-1711.
147. SEDDIKI N, SANTNER-NANAN B, MARTINSON J et al.: Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J. Exp. Med. (2006) 203(7):1693-1700.
148. FONTENOT JD, RASMUSSEN JP, GAVIN MA, RUDENSKY AY: A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat. Immunol. (2005) 6(11):1142-1151.
149. FONTENOT JD, DOOLEY JL, FARR AG, RUDENSKY AY: Developmental regulation of Foxp3 expression during ontogeny. J. Exp. Med. (2005) 202(7):901-906.
150. FONTENOT JD, RASMUSSEN JP, WILLIAMS LM et al.: Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity (2005) 22(3):329-341.
151. + regulatory T cells. Nat. Immunol. (2003) 4(4):330-336.
152. ARTIK S, HAARHUIS K, WU X, BEGEROW J, GLEICHMANN E: Tolerance to nickel: oral nickel administration induces a high frequency of anergic T cells with persistent suppressor activity. J. Immunol. (2001) 167(12):6794-6803.
153. ROELOFS-HAARHUIS K, WU X, NOWAK M et al.: Infectious nickel tolerance: a reciprocal interplay of tolerogenic APCs and T suppressor cells that is driven by immunization. J. Immunol. (2003) 171(6):2863-2872.
154. + regulatory T cells maintain immune tolerance to nickel in healthy, nonallergic individuals. J. Immunol. (2003) 171(11):5760-5768.
155. + T cell subsets against keratinocytes. J. Immunol. (2000) 165(6):3058-3064.
156. ALBANESI C, SCARPONI C, SEBASTIANI S et al.: IL-4 enhances keratinocyte expression of CXCR3 agonistic chemokines. J. Immunol. (2000) 165(3):1395-1402.
157. H2 lymphocytes, and modulates interferon-gamma- and interleukin-4-induced activation of human keratinocytes. J. Invest. Dermatol. (2000) 115(1):81-87.
158. + T lymphocytes with remarkable regulatory functions on dendritic cells and nickel-specific Th1 immune responses. J. Invest. Dermatol. (2000) 114(2):295-302.
159. + T cells. J. Invest. Dermatol. (1998) 111(4):621-628.
160. CAVANI A, ALBANESI C, TRAIDL C, SEBASTIANI S, GIROLOMONI G: Effector and regulatory T cells in allergic contact dermatitis. Trends Immunol. (2001) 22(3):118-120.
161. SCHMID S, KUECHLER PC, BRITSCHGI M et al.: Acute generalized exanthematous pustulosis - role of cytotoxic T cells in pustule formation. Am. J. Pathol. (2002) 161(6):2079-2086.
162. DRUMMOND NS, VILAR FJ, NAISBITT DJ et al.: Drug-specific T cells in an HIV-positive patient with nevirapine-induced hepatitis. Antivir. Ther. (2006) 11(3):393-395.
163. PHILLIPS EJ, WONG GA, KAUL R et al.: Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS (2005) 19(9):979-981.